Nuvalent, Inc. (NUVL)

101.22 -1.41 (-1.37%) USD  |  NASDAQ  |  Dec 17, 16:00
101.22 0.00 (0.00%) After-Hours: 20:00
More

Nuvalent Research and Development Expense (Quarterly): 83.84M for Sept. 30, 2025

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for NUVL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Pfizer Inc. 2.492B
Xencor, Inc. 54.37M
NovaBay Pharmaceuticals, Inc. --
Palatin Technologies, Inc. 2.526M
Theriva Biologics, Inc. 2.551M